Dongkook Pharmaceutical Successfully Concludes "dkma Symposium"... Sharing Total Aesthetic Solutions

Dongkook Pharmaceutical announced on March 16 that it held the "dkma Symposium" on the 14th at the Fairmont Ambassador Seoul in Yeouido, Seoul.

This symposium was organized to share treatment strategies and combination procedure know-how that can be practically applied in clinical settings, based on the major products of Dongkook Pharmaceutical's medical aesthetics brand.

Dongkook Pharmaceutical held the 'dkma Symposium' on the 14th at Fairmont Ambassador Seoul in Yeouido, Seoul. Dongkook Pharmaceutical

For the lectures that day, medical professionals specializing in cosmetic procedures participated as moderators, introducing various real-world cases and treatment methods applicable in clinical practice, based on the characteristics and their experiences with each product.

During the first session, Yonghaeng Lee, Director of Wellga Clinic, served as the moderator, while Seonghwan Ahn, Director of Gangnam Yonsei Line Clinic, presented on "Treatment strategies for achieving a smooth jawline using DCA fat-dissolving injection Milipit to improve submental fat." This was followed by Gunwoo Kim, Director of Cellenic Clinic, who shared clinical experiences with Madekiel, focusing on "Synergistic use of EBD procedures and skin boosters containing Centella Asiatica extract and chitosan."

In the second session, Jaewook Yoo, Director of Baromi Clinic, moderated, and Dongjin Lee, Director of BLS Clinic, explained "Strategies for improving facial harmony using HA fillers and botulinum toxin," detailing three-dimensional contour correction methods through combination treatments with Bellast and Vienox. Changhwan Cho, Director of Dongan Center Clinic, presented clinical cases of the new product Inhilo under the topic "New possibilities of HA skin boosters."

A marketing official at Dongkook Pharmaceutical's MA division stated, "This 'dkma Symposium' was an opportunity to introduce our newly launched HA-based injectable skin booster 'Inhilo' and share practical clinical treatment strategies based on the dkma aesthetics portfolio," adding, "We will continue to strengthen the expertise and competitiveness of the dkma brand through ongoing academic exchanges with medical professionals."

Meanwhile, Dongkook Pharmaceutical officially launched its medical aesthetics division (dkma) in 2024, and currently offers a diverse product lineup including HA fillers 'Kaveline' and 'Bellast', botulinum toxin 'Vienox', the new-concept skin booster 'Madekiel' based on madecassoside and chitosan, wound dressings 'MadekaMD Cream and Lotion', DCA fat-dissolving injection 'Milipit', and the dual HA skin booster 'Inhilo'. The company is focusing on strengthening its competitiveness in the medical aesthetics sector through academic activities both domestically and internationally, as well as offering training and hands-on product seminars for medical professionals.

This content was produced with the assistance of AI translation services.